PYXS vs. ALLO, GLUE, TKNO, GOSS, CRVS, PROK, AMRN, OLMA, TRDA, and CDTX
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Allogene Therapeutics (ALLO), Monte Rosa Therapeutics (GLUE), Alpha Teknova (TKNO), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), ProKidney (PROK), Amarin (AMRN), Olema Pharmaceuticals (OLMA), Entrada Therapeutics (TRDA), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry.
Pyxis Oncology vs. Its Competitors
Allogene Therapeutics (NASDAQ:ALLO) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
In the previous week, Pyxis Oncology had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.67 beat Pyxis Oncology's score of 0.07 indicating that Allogene Therapeutics is being referred to more favorably in the media.
Allogene Therapeutics' return on equity of -52.98% beat Pyxis Oncology's return on equity.
Allogene Therapeutics currently has a consensus price target of $8.44, indicating a potential upside of 586.54%. Pyxis Oncology has a consensus price target of $9.00, indicating a potential upside of 669.23%. Given Pyxis Oncology's higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Allogene Therapeutics.
83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Allogene Therapeutics received 259 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 81.58% of users gave Pyxis Oncology an outperform vote while only 66.21% of users gave Allogene Therapeutics an outperform vote.
Pyxis Oncology has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Allogene Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
Summary
Allogene Therapeutics beats Pyxis Oncology on 10 of the 17 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:PYXS) was last updated on 6/22/2025 by MarketBeat.com Staff
Buy PYXS Stock Free PYXS Stock Alerts